Adiponectin: action, regulation and association to insulin sensitivity

Area of Science:

• Endocrinology
• Metabolic Syndrome Research
• Adipokine Signaling

Background:

• Adiponectin is an adipocyte-specific protein implicated in insulin resistance and atherosclerosis.
• Lower adiponectin levels are observed in obese individuals, associated with insulin resistance, type 2 diabetes, and visceral adiposity.
• Reduced adiponectin may precede type 2 diabetes development.

Purpose of the Study:

• To explore the role of adiponectin in metabolic health and its potential as a therapeutic target.
• To investigate the relationship between adiponectin levels and conditions like insulin resistance and type 2 diabetes.
• To understand the mechanisms by which adiponectin influences insulin sensitivity.

Main Methods:

• Observational studies correlating adiponectin levels with obesity, metabolic syndrome features, and diabetes.
• Analysis of adiponectin's effects following administration in relevant models.
• Investigation of factors influencing adiponectin expression, including pharmacological agents and cytokines.

Main Results:

• Adiponectin levels negatively correlate with adiposity, insulin resistance, and type 2 diabetes.
• Administration of adiponectin lowers plasma glucose and enhances insulin sensitivity.
• Reduced adiponectin expression is linked to insulin resistance in animal studies.
• Thiazolidinediones increase adiponectin levels, potentially contributing to their insulin-sensitizing effects.
• Pro-inflammatory cytokines, like tumor necrosis factor-alpha, reduce adiponectin levels.

Conclusions:

• Adiponectin functions as an insulin enhancer with anti-inflammatory and anti-atherogenic properties.
• Hypoadiponectinemia is associated with insulin resistance and metabolic syndrome.
• Adiponectin holds potential as a novel therapeutic agent for metabolic syndrome and type 2 diabetes.